Repros Therapeutics : US76028H1005 / RPRX - NASDAQ

Larry I. Lipshultz, MD, Baylor College of Medicine, Professor, Scott Department of Urology, Lester and Sue Smith Chair in Reproductive Medicine, and Past President, American Society for Reproductive Medicine has agreed to serve as Lead Investigator for the Company's Phase III program and will help Repros in preparing the pivotal protocols. The studies are being designed to show that only Androxal normalizes both testosterone and sperm concentrations as compared to topical testosterone or placebo. In a small pilot study previously conducted by Repros, only Androxal resulted in normalization of both testosterone and sperm counts in a majority of subjects. In this population of men that previously used a topical testosterone, no men on testosterone or placebo exhibited normal concentrations for both measures. Per FDA recommendation, benefit will be determined by "normalization of serum testosterone levels while preserving fertility."

Dr. Lipshultz commented, "In an era when increasingly more men are turning to testosterone replacement therapy for treatment of their low testosterone, it is important to many of these men to be able to maintain normal sperm production (spermatogenesis). Androxal has the potential to play an important role in helping to maintain normal sperm production in those men for whom testosterone replacement therapy is their best treatment and for whom the maintenance of normal spermatogenesis is equally as important."

**************************************************

13.08.2010 21:58
http://www.finanznachrichten.de/...-price-listing-requirement-004.htm

Nasdaq Grants Repros Extension until October 31, 2010 to Meet Minimum Bid Price Listing Requirement

Repros Therapeutics Inc. (NasdaqCM:RPRX) today announced that Nasdaq has granted the Company until October 31, 2010 to meet the minimum bid price requirement of the Nasdaq Capital Market. Listing Rule 5550(a)(2) requires the Company to maintain a minimum bid price of $1.00 for a minimum of ten consecutive trading days. At the Company's annual stockholders' meeting held on May 17, 2010, the stockholders approved a proposal to grant the Company's board of directors the authority to effect a reverse split of its common stock within one year of such annual meeting on a basis not to exceed one share of common stock for up to five shares of common stock outstanding, if necessary, in the sole discretion of the Company's board of directors, for purposes of maintaining its listing on the Nasdaq Capital Market.

In accordance with the decision of the Nasdaq Hearings Panel, Repros has to meet all of the continued listing requirements of the Nasdaq Capital Market by October 31, 2010, or its securities will, in all likelihood, be delisted from The Nasdaq Stock Market promptly following such date.

**************************************************

HOMEPAGE: www.reprosrx.com/

realtime.bigcharts.com/...tyle=2003&size=1&mocktick=1" style="max-width:560px" alt="" />

ax

steht unmittelbar bevor...

Analyst Blog  
Repros Schedules Meeting with FDA
By: Zacks Equity Research
August 26, 2010 | www.zacks.com/stock/news/39283/...s+Schedules+Meeting+with+FDA

Biopharmaceutical company Repros Therapeutics Inc. (RPRX - Snapshot Report) recently announced that it intends to conduct a type B meeting with the US Food and Drug Administration (FDA) regarding the phase III protocol for the company’s lead pipeline candidate, Androxal. Earlier this month, the company had received a feedback from the FDA regarding the company’s plans to conduct two phase III studies with Androxal.

Repros is developing Androxal for the treatment of secondary hypogonadism in men, who want to maintain their fertility while undergoing treatment for low testosterone. Androxal could provide an advantage over existing therapies mainly due to its convenience of use - Androxal is an oral treatment whereas existing products need to be injected or are available in the form of nasal sprays, creams or gels.

Hypogonadism Market Highly Competitive

According to the Urology Channel, about 13 million men in the US experience testosterone deficiency with less than 10% receiving treatment. The company believes that approximately 70% of men having low testosterone suffer from secondary hypogonadism. This represents significant commercial potential. However, we note that the hypogonadism market is pretty crowded with Abbott Laboratories’ (ABT - Analyst Report) AndroGel holding a major share of the market.

Other currently marketed therapies include Auxilium Pharmaceutical’s (AUXL - Analyst Report) Testim. Additional competition could be just round the corner in the form of Eli Lilly’s (LLY - Analyst Report) Axiron, which is currently under FDA review. By the time Androxal gains approval, the market could be crowded with additional competitors like Endo Pharmaceutical’s (ENDP) Aveed, and BioSante Pharmaceuticals (BPAX - Snapshot Report)/Teva Pharmaceutical Industries Ltd.’s (TEVA - Analyst Report) Bio-T-Gel.

Meanwhile, Androxal has the potential to be developed for the treatment of type II diabetes as well. The company’s investigational new drug (IND) application for the diabetes indication was accepted by the FDA and Repros is now looking to commence a phase II study in hypogonadal men with type II diabetes.

Our Take

We currently have a Zacks #3 Rank (short-term “Hold” rating) on Repros. Our short-term Hold rating is based on the company’s progress in moving Androxal into phase III development. We are also encouraged to see that the FDA is allowing the company to conduct an escalating dose study that will evaluate the safety and efficacy of Proellex, Repros’ second pipeline candidate. Proellex, which is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis, was placed under full clinical hold by the FDA.

Longer-term, we have an Underperform recommendation on Repros. We are concerned about the company’s financial position and believe the company will need to raise funds shortly in order to proceed with the development of its pipeline candidates. We believe Repros will seek a development partner for Androxal, which should bring in the necessary funds.

auf der Watch habe allerdings noch nicht rein bin.

Findest Du nicht das wir charttechnisch schon im überkauftem Bereich liegen?

Wenn ich mir den RSI anschaue liegt er bei gut 80 schon recht hoch und ich weiß nicht ob jetzt die geeignete Situation zum Einstieg wäre.

Na heute mal abwarten ob die MA200 überwunden wird oder ob Sie erst einmal abprallen wird und sich die Indikatoren wieder setzen.

Statement of Changes in Beneficial Ownership (4)
- Stock Option am 25.08.2010 zu 0.60USD

1) President and CEO ih.advfn.com/p.php?pid=nmona&article=44154202
2) Vice President, R&D ih.advfn.com/p.php?pid=nmona&article=44154181

@ Brue...: ...chart-technisch korrekt analysiert!, mal sehen wohin die Reise geht

2x an MA(200)-Überwindung gescheitert (25.+26.08)
SK wieder über/am oBB (22-26.08)
MA(50) dreht nach Norden

Wie geht es hier weiter ? Kommt jetzt wieder der Absturz nach dem Scheitern ?

Rodman & Renshaw 12th Annual Healthcare Conference

September 14, 2010, 5:45 p.m. - 6:10 p.m. Eastern
The New York Palace Hotel, New York City

www.reprosrx.com/investors_events.php

 

 

Repros' Reverse Stock Split Effective Today

Written by Staff and Wire Reports  
Friday, 15 October 2010 02:48

biomedreports.com/2010101558357/...-split-effective-today.html

Repros Therapeutics (NasdaqCM:RPRX), the company that focuses on the development of oral small molecule drugs for major unmet medical needs that treat male and female reproductive disorders, announced on Thursday evening that it will put into effect its previously announced one-for-four reverse stock split of its common stock.

The company has filed a Certificate of Amendment to its Restated Certification of Incorporation to split-adjusted shares of the Company’s common stock and  will begin trading on the Nasdaq Capital Market tomorrow. The Company’s shares will continue to trade under the symbol “RPRX,” with a “D” added for 20 trading days to signify the reverse stock split has occurred.

The reverse split will reduce the Company’s outstanding common stock from approximately 35.7 million shares, as of its most recent quarterly report on Form 10-Q, to approximately 8.9 million shares.

The one-for-four reverse stock split will convert all shares of the Company’s common stock issued and outstanding, plus all outstanding stock options and the number of shares of common stock available for issuance under the Company’s approved stock plans.

The reverse split may enable the Company to meet the continued listing rules of the Nasdaq Capital Market. In order to maintain its listing on the Nasdaq Capital Market, the Company’s common stock must have a closing bid price of $1.00 or more for a minimum of ten consecutive trading days, on or before October 31, 2010.

und keiner mehr dabei...?
nach dem 8-K filing und den neu eingereichten daten bei der FDA
könnte es jetzt gewaltig up gehen...

vielleicht lebt dann der thread wieder auf!

Repros shares skyrocket on drug news
Houston Business Journal - by Greg Barr
Date: Thursday, December 23, 2010

Shares of Repros Therapeutics Inc. nearly doubled in value Thursday in heavy volume after the company reported positive developments for its experimental testosterone deficiency drug, Androxal.

Repros (NASDAQ: RPRX) said in a statement that it had sent additional data to the U.S. Food and Drug Administration showing that a single assessment of testosterone levels collected in the morning correlates to maximum and average levels of testosterone during a 24-hour period in subjects taking Androxal.

The news sent the shares of The Woodlands-based company skyrocketing to a high of $2.60, before ending Thursday's trading at $2.57, a gain of $1.16 or 82 percent from the Dec. 22 close of $1.41. More than 7.5 million of the company's 8.9 million outstanding shares changed hands during Thursday's session.

wie es weitergeht nächste woche in usa.
und ob die anleger hier im forum wieder aktiv werden.

schöne weihnachten

max

03.02.2011 21:39
www.finanznachrichten.de/...-common-stock-and-warrants-004.htm
          §
Repros Therapeutics® Announces Pricing of Public Offering of Common Stock and Warrants

Repros Therapeutics Inc.® (NasdaqCM:RPRX) today announced the pricing of its public offering of 690,000 units, (including the exercise of the underwriter's overallotment option), consisting of 2,760,000 shares of its common stock, Series A Warrants to purchase 2,070,000 shares of common stock and Series B Warrants to purchase 1,690,500 shares of its common stock, at a price per unit of $17.15. Each unit consists of four shares of common stock, Series A Warrants exercisable for three shares of common stock at an exercise price of $0.01 per share and Series B Warrants exercisable for 2.45 shares of common stock at an exercise price of $2.49 per share. Gross proceeds to Repros, after the underwriting discount and before offering expenses, are expected to be approximately $11,000,000. Upon the closing of this offering, the Series A Warrants and Series B Warrants will be listed on the Nasdaq Capital Market under the symbols "RPRXW" and "RPRXZ," respectively. The offering is expected to close on or about February 8, 2011.

... (weiter siehe LINK)

gings los ;-)

An der Nasdag rauf um+ 140%!.Warum was sind die News?.Gruß Lars

Eigentlich sollte heute eine Kursberuhigung stattfinden,ob es weiter nach oben in Richtung 4,-Dollar gehen wird muss abgewartet werden.

heftiges Teil...

An der Heimatbörse halten wir uns über die Marke von 3,- $US Dollar.Wäre klasse wenn wir diese bis zum Handelsende halten würden.Bis dato echt klasse entwickelt unter hohem Volumen.

Hat nicht ganz gereicht mit den 3,- $ Dollar als Schlusskurs. Aber trotzdem auch heute mit sehr hohen Volumen wieder +20% Prozent an der Heimatbörse. Das zeigt das Interesse an dem Unternehmen bleibt weiter sehr hoch.Mal schauen ob es morgen an der Nasdag wieder up gehen wird ?.

Am 5 Mai Q1 2016 sollen Zahlen kommen um 9 Uhr !.

oder im Morningspike Breakout? Cup and Handle im 2-Tage-Chart.
Dürfte bei Breakout Kraft haben um den Widerstand bei ca. 3 USD zu knacken für ein
Doppeltop? Ziel 1 Morgen 3.20 USD evtl auch neue Hochs wegen Shortsqueeze.

sleekmoney.com/...-28-00-consensus-pt-from-brokerages/1359450/

hier auseinanderklaffen. Müsste man normalerweise mit einer kl. Posi rein :)  

- völlig überkauft

0,40-0,45

Gewinnmitnahmen - unter 0,70 dann SL Welle  

die Shorts haben das Ruder übernommen - da wird über 0,80 alles geshortet was geht. Nur noch eine Frage von ein paar Minuten das wir richtig fallen. Natürlich nur meine Meinung und keine Handelsempfehlung

Ziel morgen im Tief 0,50$

Alles mit Ansage

de.marketscreener.com/kurs/aktie/...se-fur-2022-fes-40283250/